PROLIXIN® ORAL CONCENTRATE
Fluphenazine Hydrochloride Oral Solution USP
Prolixin Decanoate is the decanoate ester of a trifluoromethyl phenothiazine derivative. It is a highly potent behavior modifier with a markedly extended duration of effect. Prolixin Decanoate is available for intramuscular or subcutaneous administration, providing 25 mg fluphenazine decanoate per mL in a sesame oil vehicle with 1.2% (w/v) benzyl alcohol as a preservative. At the time of manufacture, the air in the vials is replaced by nitrogen.
PROLIXIN (fluphenazine) is indicated for the following:
Prolixin Decanoate (Fluphenazine Decanoate Injection) is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics).
Prolixin Decanoate has not been shown effective in the management of behavioral complications in patients with mental retardation.
Media Articles Related to Prolixin (Fluphenazine)
Patients with psychosis and addiction: disorder-specific treatment can help
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2015.10.30]
People with psychosis often develop an addiction disorder: almost one in two patients with schizophrenia are affected once during their lifetime.
Rise in numbers of teenagers given antipsychotics
Source: Bipolar News From Medical News Today [2015.07.02]
Teenagers between 13 and 18 are being treated more with antipsychotics, and mostly for conditions that do not involve psychosis, study suggests.
Published Studies Related to Prolixin (Fluphenazine)
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. [2007.03.30]
Pharmacotherapy of schizophrenia is associated with the stressful side effects...
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. [2006.04]
Sexual dysfunction is common in people suffering from schizophrenia and is reported by patients to be a significant reason for medication nonadherence. This report contains data for 27 people with schizophrenia who participated in a randomized double-blind 12-week trial of risperidone (4 mg/day), quetiapine (400 mg/day) or fluphenazine (12.5 mg/day)...
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. [2005.07]
This 12-week, double-blind study evaluated the effectiveness of risperidone (4 mg/day), quetiapine (400 mg/day), or fluphenazine (12.5 mg/day) in a stringently defined treatment-resistant population of people with schizophrenia. No differences were noted in total Brief Psychiatric Rating Scale (BPRS) or Clinical Global Impression scores among the drug groups (n = 38)...
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. [2005.01]
CONCLUSIONS: It is expected that TT(4) levels will decrease during quetiapine treatment, and this may possibly be related to competitive metabolism of thyroid hormones and quetiapine by UDP-glucuronosyltransferase. Routine monitoring of thyroid function in quetiapine-treated patients without a history of thyroid disease is not recommended.
Fluphenazine decanoate (depot) and enanthate for schizophrenia. 
CONCLUSIONS: There are more data for fluphenazine decanoate than for the
Clinical Trials Related to Prolixin (Fluphenazine)
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma [Recruiting]
The purpose of this study is to evaluate the safety and tolerability of fluphenazine in
patients with advanced multiple myeloma. The study will also describe the efficacy of this
Fluphenazine Hydrochloride for Psoriasis [Completed]
The objective of this study is to assess the safety and biologic activity of intralesional
injection of fluphenazine in adult subjects with psoriasis.
Fluphenazine Decanoate for Psoriasis [Terminated]
We are doing this research study to evaluate the effectiveness and safety of fluphenazine
decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine
decanoate is FDA (U. S. Food and Drug Administration) approved for use in people who have
schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA
for use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory
test tubes. Its usefulness and safety in people with psoriasis will be investigated in
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement [Active, not recruiting]
To determine if:
1. pathological gambling is similar to psychostimulant addiction as reflected by parallel
roles for D1 and D2 receptors in gambling and stimulant reinforcement.
2. these parallel roles are linked with gambling pathology or if they are evident in both
gamblers and controls.
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma [Completed]
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine
and to see how well it works in treating patients with refractory advanced multiple myeloma.
Reports of Suspected Prolixin (Fluphenazine) Side Effects
Neuroleptic Malignant Syndrome (3),
Drug Interaction (2),
Cardiac Disorder (2),
Brain Injury (2),
Weight Increased (2),
Myocardial Infarction (2),
Tardive Dyskinesia (2), more >>